News & Events
Dr. Klaus Giese (CEO) will present in the Start-Up Slam at the BIO-Europe 2019 conference in Hamburg on Tuesday, Nov 12.
Dr. Daniel Tondera and Dr. Jörg Kaufmann (CSO) will attend and present a poster at the 7th International mRNA Health Conference, November 11-12, 2019, in Berlin, Germany
Dr. Oliver Keil (CTO), Dr. Volker Fehring (Head of Formulation) and Dr. Klaus Giese (CEO) will attend the Creative Transformative Medicine Europe User Group Meeting to be held at the University of Strathclyde, Glasgow, on [...]
“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million in a successful seedfinancing round. The start-up presents a proprietary, innovative technology platform for the development of novel mRNA therapeutics to treat Acute Respiratory Distress Syndrome [...]
The Company was presented by Dr. Klaus Giese, Chief Executive Officer, in a pitch session of selected finalists and Pantherna’s technology & business case was awarded a joint second place.
The patent filing of our ideas with confirming experimental data is a first milestone and signals an inflection point for Pantherna said Dr. Jörg Kaufmann, Chief Scientific Officer. “Now we can openly communicate Pantherna’s R&D strategy [...]
Dr. Klaus Giese, Pantherna’s CEO, provided an overview of the Company’s R&D strategy.
Pantherna Therapeutics contracted with the Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht.
Under this contract the Institute will generate and functionally evaluate mRNA constructs designed by Pantherna.
Dr. Gerrit Maaß, Chief Financial Officer, and Dr. Klaus Giese, Chief Executive Officer, were invited to outline the Company’s future strategy to develop mRNA-based therapeutics (PanRNA Therapeutics) for vascular diseases.
Oliver is an experienced chemist with a long standing list of achievements in the field of drug delivery technologies, including the supervision of several CMC campaigns with liposomal-based nucleic acid inhibitors at Silence Therapeutics. His [...]